BACKGROUND: Both docetaxel and erlotinib improve overall survival over best supportive
care in non-small cell lung cancer (NSCLC). We assessed the effectiveness of erlotinib (E) …

Purpose A high proportion of patients with wild-type EGFR non-small cell lung cancer
(NSCLC) receive third-line therapy and beyond, with no prospective randomized trials …

7148 Background: Chemotherapy for patients≥ 70 with advanced NSCLC is associated
with survival benefits but with increased toxicity compared with younger patients. Erlotinib …

Preclinical data suggest that combined EGF receptor (EGFR) targeting with an EGFR
tyrosine kinase inhibitor and an anti-EGFR monoclonal antibody may be superior over …

Background Whether a combination of chemotherapy and erlotinib is beneficial for
advanced non-small cell lung cancer (NSCLC) remains controversial. This study aimed to …

Introduction: This phase 2 study was conducted to determine the efficacy and safety of
erlotinib alone and with bortezomib in patients with non-small cell lung cancer (NSCLC) …

7022 Background: A previous CALGB trial suggested a benefit for carboplatin-paclitaxel
(CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low …

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib
Page 1 Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of …

Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …